|
Telik, Inc. of Palo Alto, CA is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA® (Ezatiostat HCl, TLK199) for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA® (Canfosfamide HCl, TLK286) for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
 Telik Quarterly Webcast
Wednesday, November 5, 2008
4:30 pm Eastern (1:30 pm Pacific)
Click here for the webcast.
November 12, 2008
Telik Announces New TRAP Drug Discovery Agreement
November 5, 2008
Telik Announces Financial Results for 2008 Third Quarter
|
